Urogen pharma ltd. (URGN)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-121,495

-105,146

-89,890

-88,170

-83,719

-75,657

-62,026

-41,792

-29,965

-20,000

0

0

0

Adjustment to reconcile net loss to net cash from operating activities:
Depreciation and amortization

315

296

256

249

240

417

407

366

402

207

0

0

0

Amortization/Accretion on marketable securities

0

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

30,137

29,967

30,779

33,051

33,548

30,642

24,034

16,677

10,544

6,300

0

0

0

Exchange rate differences

-

-

-

-

-

-

0

0

0

-

0

0

0

Fair value adjustment of warrants for preferred shares

-

-

-

-

-

-

-

-

-

168

0

0

0

Realized loss on sale of short-term investment

-

-

-

-

-

-100

0

0

0

-

-

-

-

Amortization of right of use asset

1,157

1,028

0

0

0

-

-

-

-

-

-

-

-

Lease liability

1,098

910

0

0

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Decrease (increase) in inventory

-

-

-

-

-

-316

-137

-256

118

211

0

0

0

Decrease in accounts receivable

-

-

-

-

-

-

78

222

-18

-83

0

0

0

Increase in prepaid expenses and other current assets

871

394

531

698

-45

-318

-281

320

172

562

0

0

0

Decrease in accounts payable and accrued expenses

2,870

2,928

1,957

1,784

1,971

4,205

2,888

2,925

1,944

2,534

0

0

0

(Decrease) increase in deferred revenues

-

-

-

-

-

-650

-300

-225

-115

650

0

0

0

Decrease in employee related accrued expenses

741

1,786

2,398

1,495

2,043

2,975

1,545

1,099

636

1,263

0

0

0

Net cash used in operating activities

-88,718

-71,017

-55,301

-52,052

-45,644

-37,334

-33,009

-21,133

-16,447

-9,568

0

0

0

CASH FLOWS FROM INVESTING ACTIVITIES:
Sale of short-term investments

-

-

-

-

-

-

-

-

0

-

-

-

-

Purchase of marketable securities

0

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of marketable securities

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in restricted deposit

-

-

-

-

-

-

-

-

-

5

0

0

0

Purchases of property and equipment

377

325

157

440

532

560

689

377

265

271

0

0

0

Net cash provided by (used in) investing activities

-132,524

-145,593

-154,915

-142,589

-586

35,287

-741

-528

-366

-36,277

0

0

0

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of options into ordinary shares

2,425

3,664

0

0

0

-

-

-

-

404

0

0

0

Issuance of ordinary shares, net of issuance expenses

-

161,662

161,676

161,662

161,953

64,235

0

0

0

-

-

-

-

Issuance cost for shelf filing

0

-

-

-

-

-

-

-

-

-

-

-

0

Net cash provided by financing activities

1,834

165,250

167,205

166,065

165,671

66,421

64,165

63,780

125,949

61,585

0

0

0

(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

-219,408

-51,360

-43,011

-28,576

119,441

64,374

30,415

42,119

109,136

15,740

0

0

0

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Non-cash new lease liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash issuance cost

-

-

-

-

0

-

-

-

0

-

-

0

0

Exercise of options

-

-

-

0

0

-

-

-

-

-

-

-

-